Testosterone treatment lawsuits filed on behalf of men who allegedly suffered serious heart events due to drugs like AndroGel continue to mount in courts throughout the U.S., Bernstein Liebhard LLP reports. Most recently, a Texas man filed an AndroGel lawsuit in U.S. District Court, Northern District of Illinois, after he suffered a myocardial infarction that was allegedly caused by the medication.
Among other things, the June 2nd filing claims that AbbVie, Inc. and Abbott Laboratories did not disclose the risk for heart attacks and other cardiovascular problems associated with AndroGel. According to the complaint, the Plaintiff had no prior history of heart disease before he began using AndroGel in January 2005. He suffered a myocardial infarction in November of that same year. (Case No: 1:14-cv-04046)
“Since these drugs came under scrutiny earlier this year, our Firm has heard from numerous men who allegedly suffered life-threatening heart problems due to AndroGel and other testosterone therapies. Their accounts echo many of the allegations put forth in this lawsuit,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free and confidential case reviews to individuals who may have suffered heart attacks, strokes, deep vein thrombosis or pulmonary embolism due to their use of testosterone treatment therapies.
Testosterone Lawsuits: AndroGel and other low testosterone therapies are approved to treat hypogonadism, or low testosterone, in men who suffer from the condition due to another underlying medical condition. However, the AndroGel lawsuit recently filed in Illinois, as well as other claims involving this class of medication, allege that the manufacturers of these drugs created demand for their products by engaging in aggressive marketing that prompted men to seek testosterone replacement for symptoms associated with aging, including fatigue and low libido.
The litigation involving testosterone medications began to gain momentum in the wake of the U.S. Food & Drug Administration’s (FDA) disclosure that it was investigating heart risks associated with low testosterone therapy. According to the January 31st announcement, the agency’s review was prompted by the publication of two studies that indicated the use of testosterone replacement therapy could increase the risk that older men, as well as younger men with pre-existing heart disease, may suffer a heart attack, stroke or cardiac death.
Court documents indicate that dozens of testosterone treatment lawsuits have since been filed in courts throughout the U.S. On May 29th, the U.S. Judicial Panel on Multidistrict Litigation (JPML) heard oral arguments on proposals to consolidate all such claims in a multidistrict litigation to be established in the Northern District of Illinois. While plaintiffs originally sought the proceeding for AndroGel lawsuits, a number of defendants have asked that the litigation include all federal testosterone lawsuits, regardless of the drug involved. (In Re: AndroGel Product Liability Litigation, No. 2545, JPML)
Men who used drugs like AndroGel may be eligible to file a testosterone treatment lawsuit if they suffered a heart attack, stroke or other heart event allegedly caused by their medication. To learn more about the risks associated with testosterone drugs, please visit Bernstein Liebhard LLP’s website. Free, no-obligation legal consultations can be obtained by calling 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.